The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|May 30, 2018
Rommelag Showcases Blow-Fill-Seal Technology at Achema 2018
Author(s)Pharmaceutical Technology Editors
Rommelag will showcase its blow-fill-seal technology that collectively offers container production, aseptic filling, and container closure.
Advertisement
Rommelag will be showcasing its blow-fill-seal (BFS) technology at Achema 2018. According to Rommelag, the technology offers three advantages-container production, aseptic filling, and container closure-in one operation under closed conditions.
The BFS aseptic filling systems is a safer, more cost-efficient solution for packaging liquid and semi-solid pharmaceutical products than a bottlepack aseptic system, the company said. The company has supplemented its bottlepack range with various inspection systems that ensure maximum safety and cost-effectiveness throughout the packaging process.
For quality assurance in pharmaceutical production, Rommelag will also highlight its solutions for different needs, including equipment requirements, automatic visual inspection, tightness checks, and fully automated monitoring of critical product features within in-process control.
On the pharma services side, Rommelag will discuss the tailored system configurations it offers, the in-house support it provides for the planning phase of pharmaceutical production, and the after-sales service it provides from installation of the system by its own technicians to maintenance, repair, and complex modifications and retrofits.
Achema 2018 runs from June 11–15 in Frankfurt, Germany.
Source:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Advertisement
Advertisement